Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

S6G5T-6

Other · developed by Sol-Gel Technologies

Phase 2 Most advanced trial (none active)
SLGL Developer
1 Registered trials

What is S6G5T-6?

S6G5T-6 is a drug studied in acne vulgaris.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Dermatology
Developer
Sol-Gel Technologies, Ltd. (SLGL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02661958 Phase 2 Acne Vulgaris Completed SLGL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acne Vulgaris

More from Sol-Gel Technologies

Follow SLGL, the company behind S6G5T-6

See SLGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SLGL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.